Treats human immunodeficiency virus type 1 (HIV-1) infection. ANDA 91579, held by Macleods Pharms. Efavirenz.
As of Nov 16, 2026, ANDA 91579 (Efavirenz), held by Macleods Pharms, was first approved by FDA on May 10, 2024, with 0 approved supplements and 0 published complete response letters.
Efavirenz in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. Efavirenz is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 10, 2024 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Efavirenz600MG · tablet;oral | Efavirenz | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters